✦ LIBER ✦

123I-metaiodobenzylguanidine scintigraphy of ectopic intracranial retinoblastoma

✍ Scribed by Bomanji, J. ;Kingston, J. E. ;Hungerford, J. L. ;Britton, K. E.

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 672 KB
Volume: 17
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950170114

No coin nor oath required. For personal study only.

✦ Synopsis

Radioiodinated metaiodobenzylguani-

with ectopic intracranial retinoblastoma. It is felt that 1231 MlBC scintigraphy may have a role in detecting occult metastatic disease in these patients.

dine (MIBG) has been used for diagnostic purposes to image neural crest tumors. We report the uptake of lZ3l MlBC in a child

📜 SIMILAR VOLUMES

Cardiac [123I]metaiodobenzylguanidine sc

Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism

✍ Joong-Seok Kim; Phil-Hyu Lee; Kwang-Soo Lee; Jeong-Wook Park; Yeong-In Kim; Yong 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract The purpose of our study was to prospectively evaluate cardiac [^123^I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during t

123I-metaiodobenzylguanidine scintigraph

123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders

✍ Olivier Rascol; Ludwig Schelosky 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

## Abstract Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. ^12

Reply to Treglia et al.: 123I-metaiodobe

Reply to Treglia et al.: 123I-metaiodobenzylguanidine cardiac scintigraphy appears feasible despite proposed obstacles

✍ Donald R. Royall 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Although we are sympathetic to Reynolds and Slocum's concerns, 1 their editorial errs on several points. The authors cite deference to regulatory (presumably Food and Drug Administration) approval as a constraint. The FDA has long recognized broad physician discretion in using FDAapproved drugs or d

Kit type labelling of [123I] metaiodoben

Kit type labelling of [123I] metaiodobenzylguanidine

✍ H. Dougan; D. M. Lyster; J. S. Vincent; T. Rihela 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 451 KB

## SUmARY We have examined the labelling of [1231] HIBG by a Cu(1) catalyzed reaction in aqueous solution. We regularly obtained >99% radiochemical purity [1231] MIBG product and >97% radiochemical yield. At 100°C with 2 mg MIBG the radiochemical purity reached 85% at 2.5 Pin, 97% at 5 min and 99%

Radiochemistry, biochemistry, and kineti

Radiochemistry, biochemistry, and kinetics of131I-metaiodobenzylguanidine (MIBG) and123I-MIBG: Clinical implications of the use of123I-MIBG

✍ Shapiro, B. ;Gross, M. D. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB

Metaiodobenzylguanidine (MIBG) is actively concentrated in adrenergic neuroendocrine tissues and tumors by an active, energy- and sodium-dependent, high-affinity, saturable mechanism. This has proved successful, when labeled with 131-I or 123-I, in scintigraphically depicting pheochromocytomas and n

Meta-analysis of 123I-MIBG cardiac scint

Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders

✍ Alisha E. King; Jim Mintz; Donald R. Royall 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease